海南海藥(000566.SZ):控股子公司獲得羅沙司他化學原料藥上市申請批准通知書
格隆匯1月17日丨海南海藥(000566.SZ)公佈,公司控股子公司重慶天地藥業有限責任公司近日獲得國家藥品監督管理局核准簽發的羅沙司他《化學原料藥上市申請批准通知書》(通知書編號:2025YS00044)。
羅沙司他是一種新型的口服低氧誘導因子脯氨酰羥化酶抑制劑,可有效改善透析和非透析慢性腎臟病貧血患者的貧血症狀,提升血紅蛋白水平,其療效不劣於甚至優於紅細胞生成刺激劑。羅沙司他已在中國、日本及歐洲多個國家上市應用。該藥具有全新作用機制,與現有常規治療藥物相比,可口服給藥,在提高鐵利用率、無需靜脈補鐵等方面具有臨牀優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.